Objective To analyze the spatiotemporal evolution characteristics of the disease burden of esophageal cancer in China from 2001 to 2021, and provide scientific evidence for optimizing public health intervention strategies. Methods Data were derived from the Global Burden of Diseases (GBD 2021) database, extracting indicators including incidence, prevalence, mortality, disability-adjusted life year (DALY) rate, and years of life lost (YLL) rate for esophageal cancer in China. The Joinpoint regression model was employed to assess long-term trends in disease burden across genders and age groups, combined with age-standardization using the GBD world standard population. Average annual percentage change (AAPC) and 95% confidence intervals (CI) were calculated, and Excel 2019 was used for data collation and descriptive statistics. Results In 2021, the crude incidence, prevalence, and mortality rates of esophageal cancer in China were 22.55, 38.37, and 20.26 per 100 000 population, respectively, representing increases of 13.49%, 23.41%, and 1.30% compared to 2001. The DALY and YLL rates were 450.14 and 436.29 per 100 000, decreasing by 18.01% and 16.10% over the same period. Significant gender disparities were observed, with males exhibiting higher age-standardized incidence, prevalence, mortality, DALY, and YLL rates than females. In 2021, the male age-standardized incidence (34.29/100 000) and mortality (31.06/100 000) rates were 3.3 and 3.5 times those of females, respectively. Disease burden increased exponentially with age, peaking in the 70 to 74-year-old group for incidence, prevalence, and DALY rates, with males showing significantly higher values than females. Trend analysis of standardized rates revealed significant declines from 2001 to 2021, with AAPC values of ?2.03% for incidence, ?1.42% for prevalence, ?2.57% for mortality, and ?2.84% for DALY rate (all P<0.05). Conclusion The age-standardized disease burden of esophageal cancer in China has decreased over the past two decades, while crude rates have continued to rise, with a pronounced burden among males and older populations. Against the backdrop of accelerating population aging, targeted early screening, behavioral interventions, and optimized resource allocation are imperative to address the challenges in preventing and controlling esophageal cancer.
ObjectiveTo evaluate early effectiveness of posterior 180-degree decompression via unilateral biportal endoscopy (UBE) in the treatment of lumbar spinal stenosis (LSS) combined with Michigan State University (MSU)-1 lumbar disc herniation (LDH). MethodsA retrospective analysis was conducted on clinical data from 33 patients with LSS combined with MSU-1 LDH, who met selection criteria and were treated between March 2022 and January 2024. All patients underwent UBE-assisted 180-degree spinal canal decompression. The cohort comprised 17 males and 16 females, aged 37-82 years (mean, 67.1 years). Preoperative presentations included bilateral lower limbs intermittent claudication and radiating pain, with disease duration ranging from 5 to 13 months (mean, 8.5 months). Affected segments included L3, 4 in 4 cases, L4, 5 in 28 cases, and L5, S1 in 1 case. LSS was rated as Schizas grade A in 4 cases, grade B in 5 cases, grade C in 13 cases, and grade D in 11 cases. LDH was categorized as MSU-1A in 24 cases, MSU-1B in 2 cases, and MSU-1AB in 7 cases. Intraoperative parameters (operation time, blood loss) and postoperative hospitalization length were recorded. The visual analogue scale (VAS) score and Oswestry Disability Index (ODI) were used to assess the lower limb pain and functional outcomes after operation. Clinical efficacy was evaluated at last follow-up via modified MacNab criteria. Quantitative radiological assessments included dural sac cross-sectional area (DSCA) measurements and spinal stenosis grading on lumbar MRI. Morphological classification of lumbar canal stenosis was determined according to the Schizas grading, categorized into four grades. Results The operation time was 60.4-90.8 minutes (mean, 80.3 minutes) and intraoperative blood loss was 13-47 mL (mean, 29.9 mL). The postoperative hospitalization length was 3-5 days (mean, 3.8 days). All patients were followed up 12-16 months (mean, 13.8 months). The VAS score and ODI improved at immediate and 3, 6, and 12 months after operation compared to before operation, and the differences between different time points were significant (P<0.05). At last follow-up, the clinical efficacy assessed by the modified MacNab criteria were graded as excellent in 23 cases, good in 9 cases, and poor in 1 case, with an excellent and good rate of 96.97%. Postoperative lumbar MRI revealed the significant decompression of the dural sac in 32 cases, with 1 case showing inadequate dural expansion. DSCA measurements confirmed progressive enlargement and stenosis reduction over time. The differences were significant (P<0.05) before operation, immediately after operation, and at 6 months after operation. At 6 months after operation, Schizas grading of spinal stenosis improved to grade A in 27 cases and grade B in 6 cases. ConclusionPosterior 180-degree decompression via UBE is a safe and feasible strategy for treating LSS combined with MSU-1 LDH, achieving effective neural decompression while preserving intervertebral disc integrity.
Objective This study utilized the 2021 Global Burden of Disease database to systematically analyze global liver cancer mortality, years lived with disability, years of life lost, and disability-adjusted life years (DALY) from 1990 to 2021. It focuses on differences across genders and age groups to reveal epidemiological patterns of liver cancer attributable to high BMI, providing reference for global liver cancer prevention and control. MethodBased on the 2021 Global Burden of Disease database, the Global Health Data Exchange query tool was used to extract the total number of global liver cancer deaths, DALY, age-standardized mortality rate (ASMR), and age-standardized DALY rate from 1990 to 2021. These metrics were assessed using estimated annual percentage change. Joinpoint regression analysis was employed to calculate annual percentage change and average annual percentage change , comparing differences in subtype composition from 1990 to 2021. Smooth curve regression analysis was applied to assess the correlation between liver cancer mortality and DALY rates attributable to high BMI and the socio-demographic index (SDI). ResultsFrom 1990 to 2021, the cumulative number of liver cancer deaths attributable to high BMI increased from 10 282.12 cases in 1990 ［95%UI (4 196.72, 16 721.85)］ to 46 200.88 cases［95%UI (38 606.14, 77 983.02)］ in 2021, representing a 3.5-fold increase. DALYs attributable to high BMI-related liver cancer increased from 292,696.35 years in 1990［95%UI (119 094.56, 475 962.67)］ to 1 273 312.58 years［95%UI (504 391.1, 2,101,957.87)］ in 2021, representing a 3.2-fold increase.② Cumulative deaths attributable to high BMI: For males, deaths increased from 5,913.45 cases [95% UI (2,479.64, 9,717.69)] in 1990 to 28,511.99 cases［95%UI (11 721.81, 49 277.60)］ in 2021, representing a 3.8-fold increase. For women, the cumulative number increased from 4,368.66 cases［95%UI (1 707.64, 7 078.83)］in 1990 to 17 691.88 cases［95%UI (7 169.44, 29 573.18)］in 2021, representing a threefold increase.③ Cumulative mortality values increased across all SDI income regions to varying degrees. ASMR and death counts steadily rose with increasing age, mirroring the growth trend in DALYs attributable to liver cancer associated with high BMI. Correlation analysis and slope index results demonstrated a significant positive correlation between SDI and both death counts and DALYs. The mortality concentration index rose from –0.277 (1990) to –0.258 (2021), while the DALY concentration index increased from –0.222 (1990) to –0.208 (2021). The mortality slope index increased from 0.284 (1990) to 0.881 (2021), while the DALY rate slope index rose from 7.002 (1990) to 19.244 (2021). ConclusionsThe burden of liver cancer associated with high BMI remains substantial and varies significantly across different age groups, genders, and geographic locations worldwide. The global disease burden of liver cancer linked to high BMI is projected to remain severe in the future, necessitating sustained attention and the development of more targeted prevention and control measures tailored to current circumstances.
ObjectiveTo overview the systematic reviews/meta-analyses (SRs/MAs) of efficacy and safety of dipeptidyl peptidase-4 inhibitors (DPP-4) in treatment of type 2 diabetes mellitus (T2DM).MethodsDatabase including The Cochrane Library, PubMed, EMbase, CBM, WanFang Data and CNKI were searched from inception to December 2016 to collect SRs/MAs of randomized controlled trials (RCTs) of DPP-4 for the treatment of T2DM. Two reviewers independently screened literature, extracted data, and evaluated the reporting and methodological qualities using the PRISMA checklist and the AMSTAR tool.ResultsTwenty-seven SRs/MAs of DPP-4 for the treatment of T2DM were included in this overview. The average score of AMSTAR was 7.04. The worst score were the item 1 (26 studies didn't provide an ‘a priori’ design), item 4 (10 studies didn't provide whether the status of publication used as an inclusion criterion?), item 10 and item 11 (15 studies didn't assess the likelihood of publication bias and the potential conflicts of interest). The PRISMA score ranged from 17.0 to 24.5. The main problems of reporting were protocol and registration, search, additional analyses and funding.ConclusionThe evidence shows that the reporting and methodological quality of the SRs/MAs of DPP-4 inhibitors for type 2 diabetes are not high.
ObjectiveTo overview the systematic reviews of dominant diseases of acupuncture in clinical efficacy.MethodsPubMed, The Cochrane Library, Web of Science, CNKI, CBM, VIP and WanFang Data databases were electronically searched to collect systematic reviews or meta-analyses of dominant diseases of acupuncture in clinical efficacy from inception to December 2020. Two reviewers independently screened literature, extracted data and assessed the quality of the included studies. Then, Excel 2010 and VOS viewer were used for data analysis.ResultsA total of 263 systematic reviews were included. Acupuncture techniques involved electroacupuncture (n=29), point thread-embedding (n=25), dermal needle (n=15), acupoint injection (n=12), spoon needle (n=12), fire needle (n=8), laser (n=8), intradermal needle (n=5), filiform needle (n=4), pricking blood therapy (n=2) and round-sharp needle (n=1). A total of 94 kinds of diseases were identified, and their total effective rate ranged from 4% (bladder cancer) to 98% (bladder stones, renal colic), 72 kinds of which were above 85%.ConclusionsAcupuncture is currently widely used in clinical practice. Based on the clinical effectiveness evidence, this study finally identifies 94 types of dominant diseases. However, the total sample size and total effective rate vary considerably, and the types of acupuncture are not yet specified in this study, which requires to be focused in future research.